Virus-Like Particles (VLPs) Trends: Market Research Report
The report analyzes and presents an overview of Virus-Like Particles (VLPs) market worldwide. 'Virus-like particles or VLPs bear high structural resemblance to viruses, though completely non-infectious in nature due to the absence of viral genetic material. While lacking the DNA material, VLPs retain key immunological characteristics of viruses including particulate structures; repetitive surfaces; and capability to induce innate immunity by activating molecular-pattern pathogen-associated recognition receptors.'
The report also provides a review of types, medium of production, quantification, applications, and advantages of VLPs over conventional vaccines along with strategic industry activities of major companies worldwide. In addition, 10 companies operating in the Direct Attached Storage (DAS) arena worldwide including Cytos Biotechnology AG, Medicago Inc., Novavax Inc., Redbiotec AG, Virometix AG, VLPbio - The Vaccines Company and other are profiled.
The report also provides a review of types, medium of production, quantification, applications, and advantages of VLPs over conventional vaccines along with strategic industry activities of major companies worldwide. In addition, 10 companies operating in the Direct Attached Storage (DAS) arena worldwide including Cytos Biotechnology AG, Medicago Inc., Novavax Inc., Redbiotec AG, Virometix AG, VLPbio - The Vaccines Company and other are profiled.
1. VIRUS-LIKE PARTICLES – A TECHNOLOGY OVERVIEW
Virus-like Particles: An Introduction
Ability to Elicit Immune Response: A Unique Characteristic of VLPs
Virus-like Particles: Types
Mycovirus VLPs
Chimeric VLPs
Empty Virus-like Particles (eVLPs)
Functional Influenza VLPs
Respiratory Syncytial VLPs
Rabies Glycoprotein VLPs
Virus-like Particles: Medium of Production
Insect Cell Lines
Plant Cell Lines
Yeast Cells
Heterologous Expression Systems
Virus-like Particles: Quantification
Virus-like Particles: Applications
Vaccine Development
Treatment of Chronic Diseases
Advantages of VLP-based Vaccines over Conventional Vaccines
Comparison with Recombinant Protein Vaccines
Comparison with Chicken Egg-based Vaccines
Advantage of Using VLPs in Development of Flu Vaccine
Use of VLPs in Nanotechnology for Targeted Drug Delivery
2. NOTEWORTHY INDUSTRY ACTIVITY
Medicago and a Leading Pharmaceutical Company Ink Loan Agreement
Medicago Develops New VLP-based Vaccine Candidate againstH7N9 Virus
Novavax Commences Animal Studies on H7N9 VLP Vaccine
Medicago to Increase Production Capacity of Pilot Facility
Medicago Completes Preclinical Studies on New VLP Vaccine Candidate against Rabies
Novavax Concludes Phase I Clinical Trials on A/H5N1 Vaccine Candidate
Medicago and USAMRIID Ink Research Collaboration Agreement
Novavax Secures Contract from Biomedical Advanced Research and Development Authority
Medicago and PT Bio Farma Ink Memorandum of Understanding
Medicago Files Patent Applications for New VLP/Recombinant Proteins Production Methods
Novavax Receives US Patent for Influenza VLP Vaccine Technology
Novavax Concludes Phase II Clinical Trial on Trivalent Seasonal Influenza VLP-based Vaccine Candidate
3. MARKET PARTICIPANTS
Cytos Biotechnology AG (Switzerland)
Icosagen AS (Estonia)
Medicago, Inc. (Canada)
Medigene AG (Germany)
Novavax, Inc. (USA)
Oxford Expression Technologies Ltd. (UK)
Paragon Bioservices, Inc. (USA)
Redbiotec AG (Switzerland)
Virometix AG (Switzerland)
VLPbio - The Vaccines Company (Spain)
4. APPENDIX
Virus-like Particles: An Introduction
Ability to Elicit Immune Response: A Unique Characteristic of VLPs
Virus-like Particles: Types
Mycovirus VLPs
Chimeric VLPs
Empty Virus-like Particles (eVLPs)
Functional Influenza VLPs
Respiratory Syncytial VLPs
Rabies Glycoprotein VLPs
Virus-like Particles: Medium of Production
Insect Cell Lines
Plant Cell Lines
Yeast Cells
Heterologous Expression Systems
Virus-like Particles: Quantification
Virus-like Particles: Applications
Vaccine Development
Treatment of Chronic Diseases
Advantages of VLP-based Vaccines over Conventional Vaccines
Comparison with Recombinant Protein Vaccines
Comparison with Chicken Egg-based Vaccines
Advantage of Using VLPs in Development of Flu Vaccine
Use of VLPs in Nanotechnology for Targeted Drug Delivery
2. NOTEWORTHY INDUSTRY ACTIVITY
Medicago and a Leading Pharmaceutical Company Ink Loan Agreement
Medicago Develops New VLP-based Vaccine Candidate againstH7N9 Virus
Novavax Commences Animal Studies on H7N9 VLP Vaccine
Medicago to Increase Production Capacity of Pilot Facility
Medicago Completes Preclinical Studies on New VLP Vaccine Candidate against Rabies
Novavax Concludes Phase I Clinical Trials on A/H5N1 Vaccine Candidate
Medicago and USAMRIID Ink Research Collaboration Agreement
Novavax Secures Contract from Biomedical Advanced Research and Development Authority
Medicago and PT Bio Farma Ink Memorandum of Understanding
Medicago Files Patent Applications for New VLP/Recombinant Proteins Production Methods
Novavax Receives US Patent for Influenza VLP Vaccine Technology
Novavax Concludes Phase II Clinical Trial on Trivalent Seasonal Influenza VLP-based Vaccine Candidate
3. MARKET PARTICIPANTS
Cytos Biotechnology AG (Switzerland)
Icosagen AS (Estonia)
Medicago, Inc. (Canada)
Medigene AG (Germany)
Novavax, Inc. (USA)
Oxford Expression Technologies Ltd. (UK)
Paragon Bioservices, Inc. (USA)
Redbiotec AG (Switzerland)
Virometix AG (Switzerland)
VLPbio - The Vaccines Company (Spain)
4. APPENDIX
